Selective Versus Universal Screening for Lynch Syndrome: A Six-Year Clinical Experience

Digestive Diseases and Sciences

Volumn 60, Issue 8, 2015, Pages 2463-2469

  Kidambi, Trilokesh D ^a,b   Blanco, Amie ^a   Myers, Megan ^a   Conrad, Peggy ^a   Loranger, Kate ^a   Terdiman, Jonathan P ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE   (United States)

Author keywords

Cancer screening; Hereditary colon cancer; Immunohistochemistry; Lynch syndrome

Indexed keywords

ADULT; ARTICLE; CANCER PATIENT; CANCER RISK; CANCER SCREENING; FAMILY HISTORY; FEMALE; GENETIC COUNSELING; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HIGH RISK PATIENT; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MEDICARE; MICROSATELLITE INSTABILITY; MIDDLE AGED; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; UNIVERSITY HOSPITAL; AGED; CLINICAL PROTOCOL; COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; COMPARATIVE STUDY; EARLY DIAGNOSIS; GENETICS; MASS SCREENING; METABOLISM; MISMATCH REPAIR; PATIENT SELECTION; PROCEDURES;

NUCLEAR PROTEIN;

ADULT; AGED; CLINICAL PROTOCOLS; COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; DNA MISMATCH REPAIR; EARLY DETECTION OF CANCER; FEMALE; GENETIC COUNSELING; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MASS SCREENING; MICROSATELLITE INSTABILITY; MIDDLE AGED; NUCLEAR PROTEINS; PATIENT SELECTION; RETROSPECTIVE STUDIES;

EID: 84937526424     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-014-3234-z     Document Type: Article

References (34)

1. Umar A, Boland CR, Terdiman JP, et al. Revised bethesda guidelines for hereditary nonpolyposis colorectal cancer (lynch syndrome) and microsatellite instability. J Natl Cancer Inst. 2004;96:261–268.
2. Vasen HF, Watson P, Mecklin JP, et al. New clinical criteria for hereditary nonpolyposis colorectal cancer (hnpcc, lynch syndrome) proposed by the international collaborative group on hnpcc. Gastroenterology. 1999;116:1453–1456.
3. Lynch HT, de la Chapelle A. Hereditary colorectal cancer. N Engl J Med. 2003;348:919–932.
4. Bonadona V, Bonaiti B, Olschwang S, et al. Cancer risks associated with germline mutations in mlh1, msh2, and msh6 genes in lynch syndrome. JAMA. 2011;305:2304–2310.
5. Hampel H, Frankel WL, Martin E, et al. Screening for the lynch syndrome (hereditary nonpolyposis colorectal cancer). N Engl J Med. 2005;352:1851–1860.
6. Aaltonen LA, Salovaara R, Kristo P, et al. Incidence of hereditary nonpolyposis colorectal cancer and the feasibility of molecular screening for the disease. N Engl J Med. 1998;338:1481–1487.
7. Barnetson RA, Tenesa A, Farrington SM, et al. Identification and survival of carriers of mutations in DNA mismatch-repair genes in colon cancer. N Engl J Med. 2006;354:2751–2763.
8. Salovaara R, Loukola A, Kristo P, et al. Population-based molecular detection of hereditary nonpolyposis colorectal cancer. J Clin Oncol. 2000;18:2193–2200.
9. Ward RL, Hicks S, Hawkins NJ. Population-based molecular screening for lynch syndrome: implications for personalized medicine. J Clin Oncol. 2013;31:2554–2562.
10. Moreira L, Balaguer F, Lindor N, et al. Identification of lynch syndrome among patients with colorectal cancer. JAMA. 2012;308:1555–1565.
11. Jarvinen HJ, Aarnio M, Mustonen H, et al. Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. Gastroenterology. 2000;118:829–834.
12. Schmeler KM, Lynch HT, Chen LM, et al. Prophylactic surgery to reduce the risk of gynecologic cancers in the lynch syndrome. N Engl J Med. 2006;354:261–269.
13. Lindor NM, Petersen GM, Hadley DW, et al. Recommendations for the care of individuals with an inherited predisposition to lynch syndrome: a systematic review. JAMA. 2006;296:1507–1517.
14. Gibson J, Lacy J, Matloff E, et al. Microsatellite instability testing in colorectal carcinoma: a practical guide. Clin Gastroenterol Hepatol. 2014;12:e171.
15. Aaltonen LA, Peltomaki P, Mecklin JP, et al. Replication errors in benign and malignant tumors from hereditary nonpolyposis colorectal cancer patients. Cancer Res. 1994;54:1645–1648.
16. Terdiman JP, Gum JR Jr, Conrad PG, et al. Efficient detection of hereditary nonpolyposis colorectal cancer gene carriers by screening for tumor microsatellite instability before germline genetic testing. Gastroenterology. 2001;120:21–30.
17. Hampel H, Frankel WL, Martin E, et al. Feasibility of screening for lynch syndrome among patients with colorectal cancer. J Clin Oncol. 2008;26:5783–5788.
18. Terdiman JP. It is time to get serious about diagnosing lynch syndrome (hereditary nonpolyposis colorectal cancer with defective DNA mismatch repair) in the general population. Gastroenterology. 2005;129:741–744.
19. Mvundura M, Grosse SD, Hampel H, et al. The cost-effectiveness of genetic testing strategies for lynch syndrome among newly diagnosed patients with colorectal cancer. Genet Med. 2010;12:93–104.
20. Pinol V, Castells A, Andreu M, et al. Accuracy of revised bethesda guidelines, microsatellite instability, and immunohistochemistry for the identification of patients with hereditary nonpolyposis colorectal cancer. JAMA. 2005;293:1986–1994.
21. Schofield L, Watson N, Grieu F, et al. Population-based detection of lynch syndrome in young colorectal cancer patients using microsatellite instability as the initial test. Int J Cancer. 2009;124:1097–1102.
22. Ladabaum U, Wang G, Terdiman J, et al. Strategies to identify the lynch syndrome among patients with colorectal cancer: a cost-effectiveness analysis. Ann Int Med. 2011;155:69–79.
23. Evaluation of Genomic Applications in P, Prevention Working G. Recommendations from the egapp working group: genetic testing strategies in newly diagnosed individuals with colorectal cancer aimed at reducing morbidity and mortality from lynch syndrome in relatives. Genet Med. 2009;11:35–41.
24. Burt RW, Cannon JA, David DS, et al. Colorectal cancer screening. J Natl Compr Cancer Netw JNCCN. 2013;11:1538–1575.
25. Beamer LC, Grant ML, Espenschied CR, et al. Reflex immunohistochemistry and microsatellite instability testing of colorectal tumors for lynch syndrome among us cancer programs and follow-up of abnormal results. J Clin Oncol. 2012;30:1058–1063.
26. Cohen SA. Current lynch syndrome tumor screening practices: a survey of genetic counselors. J Genet Couns. 2014;23:38–47.
27. Bessa X, Balleste B, Andreu M, et al. A prospective, multicenter, population-based study of braf mutational analysis for lynch syndrome screening. Clin Gastroenterol Hepatol. 2008;6:206–214.
28. Heald B, Plesec T, Liu X, Pai R, et al. Implementation of universal microsatellite instability and immunohistochemistry screening for diagnosing lynch syndrome in a large academic medical center. J Clin Oncol. 2013;31:1336–1340.
29. Gritz ER, Peterson SK, Vernon SW, et al. Psychological impact of genetic testing for hereditary nonpolyposis colorectal cancer. J Clin Oncol. 2005;23:1902–1910.
30. Sharaf RN, Myer P, Stave CD, et al. Uptake of genetic testing by relatives of lynch syndrome probands: a systematic review. Clin Gastroenterol Hepatol. 2013;11:1093–1100.
31. Cross DS, Rahm AK, Kauffman TL, et al. Underutilization of lynch syndrome screening in a multisite study of patients with colorectal cancer. Genet Med. 2013;15:933–940.
32. Chubak B, Heald B, Sharp RR. Informed consent to microsatellite instability and immunohistochemistry screening for lynch syndrome. Genet Med. 2011;13:356–360.
33. Williams JL, Williams MS. Informed consent and immunohistochemistry screening for lynch syndrome. Genet Med. 2011;13:848–849.
34. Ladabaum U, Ford JM. Lynch syndrome in patients with colorectal cancer: finding the needle in the haystack. JAMA. 2012;308:1581–1583.